Drug Trial Radar · NCT07339722
A Study of LY4515100 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
209
Planned (sponsor's estimate)
Start
Jan 15, 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.
Conditions
- Healthy
Interventions
LY4515100 via SADDrug
given orally
LY4515100 via MADDrug
given orally
LY4515100Drug
given orally
ItraconazoleDrug
given orally
CaffeineDrug
given orally
DigoxinDrug
given orally
IohexolDrug
given IV
MetforminDrug
given orally
RosuvastatinDrug
given orally
PlaceboDrug
given orally
MidazolamDrug
given orally
MidazolamDrug
given IV
LevonorgestrelDrug
given orally
Ethinyl EstradiolDrug
given orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and BTime frame: Day 1 up to Day 30
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit
Dallas, Texas · Recruiting
Fortrea Clinical Research Unit
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.